Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
Curr Pharm Biotechnol. 2024;25(8):937-943. doi: 10.2174/1389201025666230905092218.
Parkinson's disease (PD) is a widespread neurodegenerative disorder that exerts a broad variety of detrimental effects on people's health. Accumulating evidence suggests that mitochondrial dysfunction, neuroinflammation, α-synuclein aggregation and autophagy dysfunction may all play a role in the development of PD. However, the molecular mechanisms behind these pathophysiological processes remain unknown. Currently, research in PD has focussed on high mobility group box 1 (HMGB1), and different laboratory approaches have shown promising outcomes to some level for blocking HMGB1. Given that HMGB1 regulates mitochondrial dysfunction, participates in neuroinflammation, and modulates autophagy and apoptosis, it is hypothesised that HMGB1 has significance in the onset of PD. In the current review, research targeting multiple roles of HMGB1 in PD pathology was integrated, and the issues that need future attention for targeted therapeutic approaches are mentioned.
帕金森病（PD）是一种广泛存在的神经退行性疾病，对人们的健康造成了广泛的不良影响。越来越多的证据表明，线粒体功能障碍、神经炎症、α-突触核蛋白聚集和自噬功能障碍都可能在 PD 的发展中发挥作用。然而，这些病理生理过程背后的分子机制尚不清楚。目前，PD 的研究集中在高迁移率族蛋白 B1（HMGB1）上，不同的实验室方法已经显示出在一定程度上阻断 HMGB1 的有前景的结果。鉴于 HMGB1 调节线粒体功能障碍，参与神经炎症，并调节自噬和细胞凋亡，因此假设 HMGB1 在 PD 的发病机制中具有重要意义。在本综述中，整合了针对 HMGB1 在 PD 病理中多种作用的研究，并提到了针对治疗方法需要未来关注的问题。
